HealthDay News — Subthalamic deep brain stimulation (DBS) is an effective long-term therapy for Parkinson disease (PD), according to a study published online September 15 in JAMA Neurology.

BPL-003 is a novel, nasal spray formulation of mebufotenin benzoate designed to deliver rapid and durable antidepressant effects from a single dose.

HealthDay News — Overdose deaths in older adults from fentanyl mixed with stimulants, such as cocaine and methamphetamine, have surged in the past 8 years, according to a study presented at the annual ...

Yuflyma is a TNF blocker approved as a citrate-free, high-concentration, interchangeable biosimilar to Humira (adalimumab).

New treatment approved for bipolar I disorder; Rinvoq IBD indications updated; blood-based test for early detection of amyloid pathology; and an oral ...

State health commissioner says risk to the public remains 'very low' as mosquito activity decreases with cooler temperatures.

Worse outcomes include greater clinical impairment, emotional distress, functional difficulties, and disability ...

The US Food and Drug Administration (FDA) announced earlier this week that the company is recalling several batches of its microwaveable rice products. Officials said the stones are naturally ...

Ulixacaltamide is a highly selective small molecule T-type calcium channel inhibitor designed to block neuronal bursting in the cerebello-thalamo-cortical circuit linked to tremor activity.

New ICD-10 diagnosis code is for patients with history of type 2 diabetes who bring blood sugar levels to a non-diabetic range below 6.5% for at least 3 months.

Iptacopan, an oral factor B inhibitor, previously received accelerated approval in 2024 under the brand name Fabhalta for IgAN, specifically to reduce proteinuria in patients at risk of rapid disease ...

The HeroTracker Sense add-on device is compatible with several commonly prescribed ashtma and COPD medications.